SAN JOSE, Calif., Feb. 9, 2026 — Anixa Biosciences reported encouraging survival observations from its ongoing Phase 1 ovarian cancer CAR-T clinical trial while announcing regulatory clearance for a protocol amendment enabling significant dose escalation. The update reflects continued clinical momentum for the company’s intra-peritoneal cell therapy program targeting recurrent ovarian cancer patients who have failed multiple prior treatments.

Science Significance

The investigational CAR-T therapy, liraltagene autoleucel (lira-cel), is designed to target the follicle-stimulating hormone receptor (FSHR), selectively expressed on ovarian tumor cells and vasculature. This receptor-directed approach enables precise tumor targeting while sparing healthy tissue, a key challenge in solid tumor immunotherapy. Clinical observations to date show multiple patients exceeding expected median survival benchmarks despite receiving low dose levels. Notably, one patient survived 28 months, while several others surpassed one-year survival — a meaningful signal in heavily pretreated populations. The therapy utilizes intra-peritoneal delivery, a localized administration method that may enhance tumor exposure while limiting systemic toxicity, representing a novel evolution in CAR-T delivery science.

Regulatory Significance

Regulatory approval of the amended clinical protocol enables dose escalation up to 100-fold higher than initial dosing levels, marking a critical Good Clinical Practice milestone. Institutional Review Board authorization supports expansion from early safety dosing ranges toward therapeutically optimized cell concentrations. Importantly, no dose-limiting toxicities have been observed to date, reinforcing the therapy’s tolerability profile and justifying escalation. The amendment also introduces lymphodepletion — a preparatory regimen using cyclophosphamide and fludarabine — to enhance CAR-T expansion and persistence. This combination strategy aligns with evolving regulatory expectations for optimizing cell therapy efficacy in solid tumors.

Business Significance

The trial’s advancement strengthens Anixa’s position within the rapidly expanding cell and gene therapy oncology market. Strategic collaboration with Moffitt Cancer Center supports clinical execution and translational research integration. Dose escalation approval enhances the program’s value inflection potential by accelerating clinical validation and investor confidence. As survival signals emerge and protocol intensity increases, the therapy’s differentiation within solid tumor CAR-T development could drive partnership, licensing, and commercialization opportunities. The company’s broader immunotherapy pipeline, including cancer vaccines, further amplifies long-term portfolio value.

Patients’ Significance

Recurrent ovarian cancer patients face limited treatment options and poor survival outcomes following chemotherapy resistance. The observed extension of survival beyond expected prognostic timelines offers early hope in a population with significant unmet medical need. Localized CAR-T delivery may reduce systemic adverse effects while enabling higher therapeutic dosing. If efficacy signals strengthen in later-phase trials, the therapy could redefine treatment pathways for advanced ovarian malignancies, potentially improving both survival and quality of life for patients with few alternatives.

Policy Significance

Advancement of solid tumor CAR-T therapies carries implications for regulatory frameworks, hospital infrastructure, and reimbursement policy. Cell therapies require specialized manufacturing, chain-of-identity controls, and clinical administration capabilities, prompting health systems to expand advanced therapy readiness. Regulatory bodies are also refining guidance on dose escalation, lymphodepletion protocols, and localized delivery models. As evidence builds, payer systems and oncology guidelines may evolve to incorporate engineered cell therapies into standard ovarian cancer care pathways.

With dose escalation authorized and survival signals emerging, Anixa’s CAR-T program enters a pivotal phase of clinical evaluation. The integration of receptor-targeted engineering, intra-peritoneal delivery, and lymphodepletion conditioning reflects a multifaceted strategy to overcome historic barriers in solid tumor immunotherapy. Upcoming higher-dose cohort data will be closely monitored to determine therapeutic durability, safety scalability, and the pathway toward late-stage development and regulatory approval.

Source: Anixa Biosciences press release